[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Konkuk University Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":267},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,44,76,99,131,159,185,214,239],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100648231","ori-guided-oxygen-therapy-during-one-lung-ventilation-100648231",false,"NCT07720778","ORI-Guided Oxygen Therapy During One-Lung Ventilation","Effect of Oxygen Reserve Index-Guided Fraction of Inspired Oxygen Titration on the Incidence of Hyperoxemia During One-Lung Ventilation","ORI-OLV","Inclusion Criteria:\n\n* Adults aged ≥19 years\n* Scheduled for elective lung surgery requiring one-lung ventilation\n* Written informed consent\n\nExclusion Criteria:\n\n* Severe pulmonary hypertension.\n* Left ventricular systolic dysfunction.\n\nWithdrawal Criteria:\n\n* The participant or legally authorized representative requests withdrawal from the study.\n* An adverse event occurs that precludes continued participation in the study.\n* The planned surgery or study procedures are not performed (e.g., ORI monitoring is not applied or arterial blood gas analysis is not performed).\n* Perfusion Index is less than 2 during the study.\n* A major violation of the inclusion or exclusion criteria is identified after enrollment.\n* The participant fails to comply with the study protocol, potentially affecting the validity of the study outcomes.\n* Continued participation is considered not to be in the participant's best interest.\n* In the investigator's judgment, any other condition arises that makes continued participation inappropriate.","ALL","19 Years",{"count":20,"type":21},58,"ESTIMATED","INTERVENTIONAL",[24],"NA","High inspired oxygen concentrations (FiO₂) are commonly administered during general anesthesia to prevent hypoxemia. However, excessive oxygen administration may result in hyperoxemia, which has been associated with impaired hypoxic pulmonary vasoconstriction, increased oxidative stress, ventilation-perfusion mismatch, and postoperative pulmonary complications.\n\nDuring one-lung ventilation (OLV) for thoracic surgery, higher FiO₂ is often required because of increased intrapulmonary shunting, making hyperoxemia a frequent occurrence. The Oxygen Reserve Index (ORI) is a noninvasive pulse oximetry-derived parameter that reflects moderate hyperoxemia (PaO₂ approximately 100-200 mmHg) and may facilitate more precise oxygen titration than pulse oximetry alone.",[27],"Thoracic Surgery With One-lung Ventilation",[29,30],"One-Lung Ventilation","hyperoxia","NOT_YET_RECRUITING","2026-07-17",{"date":34,"type":35},"2026-07-22","ACTUAL",{"date":37,"type":21},"2026-08-01",{"date":39,"type":21},"2028-04-30",{"name":41,"class":42},"Konkuk University Medical Center","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":43},"100527158","phase-4-prothrombin-complex-concentrate-vs-fresh-frozen-plasma-in-goal-directed-bleeding-management-in-cardiac-surgery-100527158","NCT06144125","Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Cardiac Surgery","Prothrombin Complex Concentrate and Fresh Frozen Plasma in Viscoelastic Test-based Goal-directed Bleeding Management in Cardiac Surgery","Inclusion Criteria:\n\n* patients undergoing cardiac surgery\n\nExclusion Criteria:\n\n* thrombocytopenia\n* oral anti-coagulant\n* anti platelet agents",true,"20 Years","75 Years",{"count":55,"type":21},100,[57],"PHASE4","The primary endpoint of this study is the completion time of hemostasis treatment when administered Fresh frozen plasma (FFP) and frozen powder coagulation factor concentrate (PCC) in goal-directed bleeding management for cardiac surgery.",[60],"Cardiac Valve Disease",[62,63,64,65,66],"prothrombin complex concentrate","fresh frozen plasma","coagulation","bleeding","cardiac surgery","RECRUITING","2026-06-15",{"date":70,"type":35},"2026-06-17",{"date":72,"type":35},"2026-03-27",{"date":74,"type":21},"2026-10-30",{"name":41,"class":42},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":43},"100395297","phase-4-efficacy-and-safety-of-cerebrolysin-on-prolonged-disorders-of-consciousness-100395297","NCT04427241","Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness","Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness in Patients With Hemorrhagic Stroke: A Pilot Study","Inclusion Criteria\n\n1. Patients with hemorrhagic stroke confirmed by CT or MRI\n2. Patients who have been in disorders of consciousness for more than 4 weeks after the onset of hemorrhagic stroke\n3. Patients in a vegetative state or minimally conscious state (Coma Recovery Scale -revised: CRS-R assessment)\n4. Age: 19 to 80 years of age\n5. Patients who have voluntarily given written informed consent to participate in the study by themselves or their legal representative.\n\nExclusion Criteria\n\n1. Patients with confirmed epileptiform discharges on EEG\n2. Patients with brain parenchymal defects\n3. Patients with advanced liver, kidney, cardiac, or pulmonary disease.\n4. Chronic treatment with medications that may affect consciousness, such as antidepressants, antipsychotic drugs, nootropic drugs, and vasodilators.\n5. History of serious illness within the last two years (cancer, hematologic, renal, hepatic, or coronary artery disease, psychiatric illness, diabetes, myocardial infarction, epilepsy), no evidence of secondary damage to major organs, and well-controlled diabetes or hypertension.\n6. Alcohol or drug abuse or dependence within the last 2 years (DSM-V criteria).\n7. Significant systemic disease or unstable medical condition that may compromise compliance with the study protocol.\n8. Administration of a contraindicated drug is essential for medical purposes.\n9. Contraindications to the study drug (cerebrolysin).\n10. Participation in another therapeutic study","120 Years",{"count":85,"type":21},12,[57],"Object: To determine the effect of cerebrolysin on prolonged disorders of consciousness caused by hemorrhagic stroke.\n\nParticipants: patients with prolonged disorders of consciousness due to severe traumatic brain injury\n\nIntervention: 30 ml cerebrolysin + 70 ml normal saline, days 4-17, once\u002Fday, intravenously or 100 ml normal saline, days 4-17, once\u002Fday, IV\n\nComparison: cerebrolysin group versus control group\n\nOutcome: Coma Recovery Scale-revised, FDG-PET signal",[89,90],"Disorder of Consciousness","Hemorrhagic Stroke","2026-05-06",{"date":93,"type":35},"2026-05-11",{"date":95,"type":35},"2023-06-01",{"date":97,"type":21},"2026-12-31",{"name":41,"class":42},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":119,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100565112","comparison-of-the-diagnosis-time-of-vet-and-scl-in-patients-with-intraoperative-coagulopathy-100565112","NCT06637943","Comparison of the Diagnosis Time of VET and SCL in Patients With Intraoperative Coagulopathy","Comparison of Time Taken for Diagnosing Intraoperative Coagulopathies: Point-of-care Viscoelastic Tests vs Standard Central Laboratory Tests","Inclusion Criteria:\n\n* patients who will undergo elective surgery with a high risk of moderate to severe amount of intraoperative bleeding or coagulopathy (e.g., cardiac surgery, joint replacement, spine surgery, hepatectomy, radical prostatectomy)\n* patients who provide written informed consent\n* patients who may warrant the intraoperative use of POC viscoelastic test or SCL test\n\nExclusion Criteria:\n\n* pregnancy\n* withdrawal of consent\n* termination of surgery without performing either POC viscoelastic test or SCL tests\n* when the study conductor deems it inappropriate to proceed with the protocol with the patient",{"count":107,"type":21},210,"OBSERVATIONAL","The present study is a prospective, multi-center observational trial comparing the times taken to diagnose coagulopathies using point-of-care (POC) viscoelastic tests or standard central laboratory tests (SCL tests) in patients with intraoperative bleeding.",[111,112,113,114,115,116,117,118],"Arthritis of Knee","Arthritis of Hip","Spine","Prostate Cancer","Hepatic Cancer","Valvular Disorder","Ischemic Heart Disease","Aortic Diseases",[120,121,64],"viscoelastic test","standard central laboratory test","2025-12-01",{"date":124,"type":35},"2025-12-08",{"date":126,"type":21},"2026-02-01",{"date":128,"type":21},"2026-05-31",{"name":41,"class":42},4,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":51,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":43},"100527157","phase-4-fibrinogen-concentrates-versus-cryoprecipitate-in-liver-transplant-surgery-100527157","NCT06144112","Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery","A Randomized Trial Comparing the Time for Managing Intraoperative Hypofibrinogenemia Using Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery (FIBCRYO-LT Trial)","Inclusion Criteria:\n\n* Liver disease undergoing Liver transplantation\n\nExclusion Criteria:\n\n\\-",{"count":139,"type":21},92,[57],"We compared the time consumed for goal-directed management of hypofibrinogemia using two strategies during liver transplant (LT) surgery: a conventional cryoprecipitate-based strategy versus a lyophilized fibrinogen concentrate-based strategy",[143],"Liver Diseases",[145,146,147,148,149,150],"hypofirinogenemia","coagulopathy","fibrinogen","cryoprecipitate","liver transplantation","lyophilized factor concentrates","2025-07-16",{"date":153,"type":35},"2025-07-20",{"date":155,"type":21},"2025-09-01",{"date":157,"type":21},"2026-03-31",{"name":41,"class":42},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100501214","goal-directed-vs-empirical-tranexamic-acid-administrationin-cardiovascular-surgery-100501214","NCT05806346","Goal-directed vs. Empirical Tranexamic Acid Administrationin Cardiovascular Surgery","Tranexamic Acid Administration Strategies in Cardiovascular Surgery: Goal-directed Tranexamic Acid Administration Based on Viscoelastic Test vs. Empirical Tranexamic Acid Administration","Inclusion Criteria:\n\n* patients who will undergo elective cardiovascular surgery employing cardiopulmonary bypass\n* patients who provide written informed consent\n\nExclusion Criteria:\n\n* pregnancy\n* refusal of allogenic blood transfusion\n* taking thrombin\n* history of thromboembolic and familial hypercoagulability disease\n* recent history of myocardial infarction or ischemic cerebral infarction (within 90 days)\n* hypersensitive to TXA\n* histroy of convulsion or epilepsy\n* taking hemodialysis\n* history of Heparin-induced thrombocytopenia",{"count":167,"type":21},764,[24],"The present study is a multi-center randomized prospective placebo-controlled non-inferiority trial.\n\nThe study's primary objective is to compare the amounts of postoperative bleeding using two different TXA administration strategies: empirical TXA administration vs. viscoelastic test-based goal-directed TXA administration in cardiovascular surgery.\n\nThe secondary objectives include comparing the incidents of hyper-fibrinolysis, thromboembolic complications, and postoperative seizures.\n\nResearchers assumed that goal-directed tranexamic acid (TXA) administration using viscoelastic field tests would not be inferior to the empirical TXA administration strategy in reducing postoperative bleeding and hyper-fibrinolysis. It also would be beneficial in lowering TXA-induced thromboembolic complications and seizures.",[171,172,173,174,175],"Heart Diseases","Vascular Diseases","Transfusion Related Complication","Coagulation Disorder, Blood","Fibrinolysis; Hemorrhage","2024-12-15",{"date":178,"type":35},"2024-12-18",{"date":180,"type":35},"2023-08-01",{"date":182,"type":21},"2025-06-30",{"name":41,"class":42},3,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":201,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":213},"100567141","mild-anh-on-pre-bypass-coagulation-function-during-cardiac-surgery-100567141","NCT06664320","Mild ANH on Pre-bypass Coagulation Function During Cardiac Surgery","Impact of Mild Acute Normovolemic Hemodilution on Pre-bypass Coagulation Function During Cardiac Surgery","Inclusion Criteria:\n\n* patients undergoing cardiac surgery with cardiopulmonary bypass who signed written informed consent\n\nExclusion Criteria:\n\n* preoperative renal failure requiring reran replacement therapy\n* preoperative liver disease\n* preoperative low cardiac output (EF \\\u003C 50%)\n* Preoperative IABP application, Atrial fibrillation, Pacemaker\n* contraindication for applying TEE\n* intraoperative withdrawal","65 Years",{"count":194,"type":21},70,[24],"The impact of acute normovolemic hemodilution (ANH) using hydroxyethyl starch before initiating cardiopulmonary bypass (CPB) on whole blood viscoelastic profile after CPB has not been well established. Patients undergoing cardiac surgery employing moderate hypothermic CPB are randomly allocated into one of two groups: in Group-ANH, ANH is applied by using a balanced hydroxyethyl starch (HES 130\u002F0.6); and in Group-C, ANH is not applied. After weaning from CPB, intergroup differences of INTEM, EXTEM, FIBTEM, and APTEM profiles are analyzed. As a primary outcome, the inter-group differences between maximal clot firmness of EXTEM will be determined at 10 min after ANH in Group-ANH and that at control.",[198,199,200],"Mitral Regurgitation","Mitral Stenosis","Tricuspid Regurgitation",[202,66,203,204,64],"rotational thromboelastometry","acute normovolemic hemodilution","hemodilution","2024-10-30",{"date":207,"type":35},"2024-10-31",{"date":209,"type":21},"2024-10-28",{"date":211,"type":21},"2025-04-30",{"name":41,"class":42},2,{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":43},"100560242","effect-of-mtx-discontinuation-on-shingrix-response-in-ra-100560242","NCT06574594","Effect of MTX Discontinuation on Shingrix Response in RA","Effect of Methotrexate Discontinuation on Immunogenicity of Shingrix in Patients With Rheumatoid Arthritis","Inclusion Criteria:\n\n* fulfill 2010 ACR\u002FEULAR classification criteria for rheumatoid arthritis\n* age over 19 years\n* methotrexate user\n* agree for vaccination with shingrix\n\nExclusion Criteria:\n\n* have other form of inflammatory arthritis or autoimmune-mediated disease\n* malignancy, current infection, pregnancy",{"count":222,"type":21},110,[24],"The goal of this clinical trial is to learn if methotrexate discontinuation affect on immunogeneity of shingrix in RA patients. The main questions it aims to answer are:\n\nDiscontinuation of methotrexate after shingrix immunization increase efficacy of the vaccine in patients with RA ?\n\nResearchers will compare humoral and cell-mediated immunity against herpes zoster in RA patients who are vaccinated by shingrix, and compare these immunity between RA patients with MTX discontinuation and MTX continuation groups.\n\nParticipants will:\n\nVaccinated with shingrix twice. MTX continuation group will keep taking MTX after shingrix vaccination, whereas MTX discontinuation group will stop MTX for 2 weeks after shingrix vaccination.\n\nVisit the clinic at baseline (first shingrix vaccination), 2 months later for 2nd shingrix vaccination, then 3 \\& 6 months later from baseline to achieve blood sample.",[226],"Rheumatoid Arthritis",[228,229,230],"herpes zoster","Shingrix","methotrexate","2024-08-25",{"date":233,"type":35},"2024-08-28",{"date":235,"type":21},"2024-08-22",{"date":237,"type":21},"2025-12-31",{"name":41,"class":42},{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":43},"100475292","phase-2-neoadjuvant-lazertinib-therapy-in-egfr-mutation-positive-lung-adenocarcinoma-detected-by-balf-liquid-biopsy-100475292","NCT05469022","Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy","A Phase II, Single-Center, Single-Arm, Prospective Study of Neoadjuvant Lazertinib Therapy in Resectable EGFR-Mutation Positive Lung Adenocarcinoma Patients Detected by Broncho-alveolar Lavage Fluid(BALF) Liquid Biopsy","Inclusion Criteria:\n\n1. Age ≥ 19 years\n2. Patients with suspected lung cancer on chest CT findings\n3. Patients with the following EGFR gene mutations in the test on bronchoalveolar lavage fluid: E19Del, L858R alone or concurrent rare EGFR gene mutations (T790M, G719X, exon 20 insertion, S768I)\n4. Patients whose tumor can be completely resected by surgery: patients with stage I-IIIB, or stage IVA who has single metastasis\n5. Patients not previously treated with EGFR-TKIs such as gefitinib, erlotinib, afatinib, dacomitinib\n6. Patients with the measurable lesion of 1 cm or more according to RECIST v1.1\n7. Eastern Cooperative Oncology Group (ECOG) 0-1\n8. EGFR-TKIs (gefitinib, erlotinib, afatinib,dacomitinib) naive patients\n9. Patients with adequate pulmonary and heart function for surgery\n10. Adequate organ function defined as Hemoglobin ≥ 9.0g\u002FdL Absolute neutrophil count ≥ 1500\u002Fmm3 Platelet ≥ 100,000 \u002Fmm3 Serum creatinine≤ normal range\\*1.5x Aminotransferase\u002FAlkaline phosphatase ≤normal range\\*2.5x Total bilirubin ≤1.5 mg\u002FdL Liver metastasis: Aminotransferase\u002FAlkaline phosphatase ≤ normal range\\* 5x Bone metastasis Alkaline phosphatase ≤ normal range\\* 5x\n11. Female patients with childbearing potential should be using adequate contraceptive measures. Female patients must have evidence of non-child-bearing potential(Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments)\n12. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception for at least 14 days prior to administration of the first dose of study treatment, during the study, and for 3 months following the last dose of Lazertinib.\n\nExclusion Criteria:\n\n1. Uncontrolled active interstitial lung disease\n2. Pathologically confirmed N3 disease\n3. Uncontrolled stage III-IV other malignancy\n4. Uncontrolled Hypertension, Congestive Heart failure with New York Heart Association(NYHA) ≥ 3, acute myocardial infarct history within 6 months before screening. 2nd- 3rd Atrio-Ventricular(AV) block or complete AV block\n5. Gastrointestinal diseases (e.g. Chron's disease, ulcerative colitis) or malabsorption syndrome that would impact on drug absorption\n6. Active infection requiring ongoing treatment(e.g. active Hepatitis B virus, Hepatitis C virus or Human immunodeficiency virus)\n7. History of hypersensitivity to active or inactive excipients of Lazertinib or drugs with a similar chemical structure.\n8. No ability to comply with protocol requirements.",{"count":247,"type":21},40,[249],"PHASE2","Complete surgical resection is the standard treatment in early-stage lung cancer. However, the patients with early resected Epidermal Growth Factor Receptor(EGFR)-mutated lung cancers have high recurrence rate. The efficacy of neoadjuvant treatment by first-generation EGFR-Tyrosine Kinase Inhibitor(TKI) has been demonstrated, however, that of the third-generation EGFR-TKI(lazertinib) has not yet been fully investigated. The aim of this study is to evaluate the efficacy of neoadjuvant Lazertinib in resectable EGFR mutation-positive NSCLC and clinical application of extracellular vesicles(EVs) based BALF liquid biopsy to identify EGFR mutation without invasive tissue biopsy.",[252],"Non Small Cell Lung Cancer",[254,255,256,257,258],"EGFR mutation","extracellular vesicle","bronchoalveolar lavage","liquid biopsy","lazertinib","2022-07-20",{"date":261,"type":35},"2022-07-21",{"date":263,"type":35},"2022-05-19",{"date":265,"type":21},"2027-05-19",{"name":41,"class":42},""]